UROTHELIAL CARCINOMA

This early-phase study tested a new drug called TPST-1495, alone or with another drug (pembrolizumab), in 89 people with advanced solid tumors (like colorectal, lung, or head and neck cancer) that had stopped responding to standard treatments. The main goal was to find the safest…

This early-stage study tested a combination of two drugs—avelumab (an immunotherapy) and docetaxel (a chemotherapy)—in 21 people with advanced bladder cancer that had stopped responding to standard platinum chemotherapy. The goal was to see if the combination was safe and could s…

This study tested a new drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was completed, …

This early-stage study tested a new treatment for people with advanced bladder, skin (melanoma), or head and neck cancers. Doctors took patients' own immune cells, modified them in a lab to better recognize and attack cancer cells, and then infused them back. The main goal was to…

This study looked at how well the drug avelumab works as a maintenance treatment for people with advanced or metastatic bladder cancer (urothelial carcinoma) after initial chemotherapy. Researchers tracked 596 patients in France to measure overall survival and other outcomes in r…

This study tested whether adding lenvatinib to pembrolizumab (immunotherapy) helps people with advanced bladder cancer live longer or delay cancer growth. It included 505 participants who could not take standard platinum chemotherapy. The trial was stopped early because an indepe…

This study tested several immunotherapy drug combinations in 272 people with advanced bladder cancer that had worsened after chemotherapy. The goal was to see if these combinations could shrink tumors or slow the cancer's growth. The flexible 'umbrella' design allowed researchers…

This study tested a drug called sacituzumab govitecan given before bladder removal surgery in 44 people with muscle-invasive bladder cancer who could not take or refused standard cisplatin chemotherapy. The goal was to see if the drug could completely eliminate the tumor by the t…

This study tested a combination of two drugs (toripalimab and gemcitabine) given before surgery to people with muscle-invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. The goal was to see how well the drugs shrink tumors before the bladder is remov…

This study tested a breath analysis device (eNose) to see if it can predict which cancer patients will benefit from immunotherapy. Researchers collected breath samples from 190 adults with lung, melanoma, bladder, kidney, or head and neck cancers before treatment. The goal was to…

This study looked at how well a urine test called Cxbladder can detect bladder cancer in 682 people who had blood in their urine. The test was compared to the standard method, cystoscopy, to see if it could correctly identify who has cancer and who does not. The goal is to find a…

This study explored whether the proteins from gut bacteria differ between bladder cancer patients who respond to immunotherapy and those who do not. Researchers collected stool and blood samples from 40 patients to compare these protein profiles. The goal was to find a way to pre…